中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.022 seconds)

    Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion
    2.
    发明授权
    Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion 有权
    使用α-甲基葡糖苷（AMG）作为葡萄糖吸收和排泄指标的方法

    公开(公告)号：US08147801B2

    公开(公告)日：2012-04-03

    申请号：US12881695

    申请日：2010-09-14

    Applicant: Keith T. Demarest ,  James M. Lenhard ,  Gregory C. Leo ,  Yin Liang ,  Tonya L. Martin

    Inventor： Keith T. Demarest ,  James M. Lenhard ,  Gregory C. Leo ,  Yin Liang ,  Tonya L. Martin

    IPC: A61K49/00

    CPC classification number: G01N33/5088 ,  A61K49/0004 ,  Y10T436/142222

    Abstract: Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.

    Abstract translation: 这里提出的是在体内使用α-甲基葡糖苷（AMG）作为胃肠道（GI）系统葡萄糖吸收的指示剂或口服AMG后尿液中的葡萄糖排泄的方法。 该方法可用于例如但不限于确定动物中钠依赖性葡萄糖转运蛋白（SGLT）抑制剂的作用，比较动物中第一和第二SGLT抑制剂的作用的差异，以及 诊断与胃肠道（GI）系统的葡萄糖吸收相关的疾病或来自动物的肾脏的葡萄糖排泄。

    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol
    3.
    发明授权
    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol 有权
    用于增加HDL-C，较低LDL-C和较低胆固醇的苯并氮杂氧 - 乙酸衍生物作为PPAR-δ激动剂

    公开(公告)号：US08633184B2

    公开(公告)日：2014-01-21

    申请号：US12689335

    申请日：2010-01-19

    Applicant: Gee-Hong Kuo ,  Yan Zhang ,  Lan Shen ,  Songfeng Lu ,  Keith T. Demarest ,  Patricia Pelton

    Inventor： Gee-Hong Kuo ,  Yan Zhang ,  Lan Shen ,  Songfeng Lu ,  Keith T. Demarest ,  Patricia Pelton

    IPC: A61P1/18 ,  A61P3/06 ,  A61P3/10 ,  A61K31/55 ,  C07D223/16

    CPC classification number: C07D409/06 ,  C07D223/16 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

    Abstract: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

    Abstract translation: 本发明涉及用作PPAR激动剂的式（I）化合物。 治疗一种或多种病症的药物组合物和方法，包括但不限于糖尿病，肾病，神经病，视网膜病，多囊卵巢综合征，高血压，缺血，中风，肠易激综合征，炎症，白内障，心血管疾病，代谢综合症， 还描述了使用本发明化合物的超低密度脂蛋白胆固醇血症，血脂异常（包括高甘油三酯血症，高胆固醇血症，混合性高脂血症和低HDL-胆固醇血症），动脉粥样硬化，肥胖症和与脂质代谢和能量内环境平衡并发症相关的其它障碍。

    Substituted spiroheterocycles
    4.
    发明授权
    Substituted spiroheterocycles 有权
    取代螺旋环

    公开(公告)号：US07825110B2

    公开(公告)日：2010-11-02

    申请号：US11857891

    申请日：2007-09-19

    Applicant: Min A. Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith T. Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael J. Costanzo ,  Stephen C. Yabut

    Inventor： Min A. Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith T. Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael J. Costanzo ,  Stephen C. Yabut

    IPC: A61P9/00 ,  A61K31/55 ,  C07D223/14

    CPC classification number: C07D487/10

    Abstract: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    Abstract translation: 本发明涉及式I的非肽取代的螺杂肼苯并氮平，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加的血管阻力和心脏功能不全（包括充血性心力衰竭，低钠血症和高血压）的那些。 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，低钠血症，肾血管痉挛，肾功能不全，肾衰竭，糖尿病性肾病，脑水肿， 还公开了脑缺血，中风，血栓形成或保水。

    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol
    5.
    发明授权
    Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol 有权
    用于增加HDL-C，较低LDL-C和较低胆固醇的苯并氮杂氧 - 乙酸衍生物作为PPAR-δ激动剂

    公开(公告)号：US07678786B2

    公开(公告)日：2010-03-16

    申请号：US11736221

    申请日：2007-04-17

    Applicant: Gee-Hong Kuo ,  Yan Zhang ,  Lan Shen ,  Songfeng Lu ,  Keith T. Demarest ,  Patricia Pelton

    Inventor： Gee-Hong Kuo ,  Yan Zhang ,  Lan Shen ,  Songfeng Lu ,  Keith T. Demarest ,  Patricia Pelton

    IPC: A61P1/18 ,  A61P3/06 ,  A61P3/10 ,  A61K31/55 ,  C07D223/16

    CPC classification number: C07D409/06 ,  C07D223/16 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

    Abstract: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

    Abstract translation: 本发明涉及用作PPAR激动剂的式（I）化合物。 治疗一种或多种病症的药物组合物和方法，包括但不限于糖尿病，肾病，神经病，视网膜病，多囊卵巢综合征，高血压，缺血，中风，肠易激综合征，炎症，白内障，心血管疾病，代谢综合症， 还描述了使用本发明化合物的超低密度脂蛋白胆固醇血症，血脂异常（包括高甘油三酯血症，高胆固醇血症，混合性高脂血症和低HDL-胆固醇血症），动脉粥样硬化，肥胖症和与脂质代谢和能量内环境平衡并发症相关的其它障碍。

    BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
    9.
    发明申请
    BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL 有权
    作为用于增加HDL-C，低LDL-C和较低胆固醇的PPAR-DELTA激动剂的苯扎维林氧化胆酸衍生物

    公开(公告)号：US20100120748A1

    公开(公告)日：2010-05-13

    申请号：US12689335

    申请日：2010-01-19

    Applicant: Gee-Hong Kuo ,  Yan Zhang ,  Lan Shen ,  Songfeng Lu ,  Keith T. Demarest ,  Patricia Pelton

    Inventor： Gee-Hong Kuo ,  Yan Zhang ,  Lan Shen ,  Songfeng Lu ,  Keith T. Demarest ,  Patricia Pelton

    IPC: A61K31/55 ,  A61P3/10 ,  A61P3/04 ,  A61P7/00

    CPC classification number: C07D409/06 ,  C07D223/16 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

    Abstract: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

    Abstract translation: 本发明涉及用作PPAR激动剂的式（I）化合物。 治疗一种或多种病症的药物组合物和方法，包括但不限于糖尿病，肾病，神经病，视网膜病，多囊卵巢综合征，高血压，缺血，中风，肠易激综合征，炎症，白内障，心血管疾病，代谢综合症， 还描述了使用本发明化合物的超低密度脂蛋白胆固醇血症，血脂异常（包括高甘油三酯血症，高胆固醇血症，混合性高脂血症和低HDL-胆固醇血症），动脉粥样硬化，肥胖症和与脂质代谢和能量内环境平衡并发症相关的其它障碍。

Patent Agency Ranking